Clinical features of chronic hepatitis B patients with lean nonalcoholic fatty liver disease

Abstract Background The clinical features have been well described in obese chronic hepatitis B (CHB) patients with nonalcoholic fatty liver disease (NAFLD). However, little is known about the clinical features of lean CHB‐NAFLD patients. Methods The study retrospectively included treatment‐naïve CHB patients who underwent ultrasound between 2015 and 2021. Liver fibrosis was assessed by aspartate aminotransferase (AST) to platelet ratio index (APRI), Fibrosis‐4 score (FIB‐4), NAFLD fibrosis score (NFS), and transient elastography. Results Among 1226 CHB‐NAFLD patients, 25.0% patients were lean. The age, gender, and platelet, alanine aminotransferase, AST, and albumin levels were comparable between lean CHB‐NAFLD and nonlean patients. The levels of plasma glucose, triglycerides, total cholesterol, and uric acid, as well as proportions of concurrent hypertension and diabetes, were lower in lean patients. Lean patients presented higher hepatitis B surface antigen (HBsAg) levels (3.4 log 10 IU/ml vs. 3.2 log 10 IU/ml, p = 0.006), hepatitis B virus (HBV) DNA levels (4.1 log 10 IU/ml vs. 3.2 log 10 IU/ml, p < 0.001), and hepatitis B e antigen (HBeAg) positive proportions (40.4% vs. 30.2%, p = 0.002) than nonlean patients. The values of APRI, FIB‐4, and liver stiffness were comparable between two groups. However, lean patients had lower NFS values (−3.0 vs. −2.6, p < 0.001) and lower proportions (12.6% vs. 21.1%, p = 0.003) of advanced fibrosis (NFS ≥ −1.5) than nonlean patients. Similar results were observed in HBeAg‐positive and HBeAg‐negative subgroups. Conclusions Nearly a quarter of CHB‐NAFLD patients were lean. Lean patients had lower proportions of metabolic abnormalities and advanced liver fibrosis than nonlean patients. However, lean CHB‐NAFLD patients had higher HBsAg levels, HBV DNA levels, and HBeAg‐positive proportions. Registry and registration no. of the study/trial: Clinicaltrials.gov, Identifier: NCT03097952.